Close Menu

Bio-Rad

Among firms presenting on the first day, 10x Genomics revealed it is developing a new high-throughput Chromium instrument, and Guardant plans to launch a comprehensive tissue sequencing assay.

Bio-Rad's year-over-year Q3 revenue increase was driven primary by sales of PCR and Droplet Digital PCR products due to the COVID-19 pandemic.

The firm is using ddPCR to support testing 3,000 samples per day with a turnaround time of approximately 24 hours

The court also ordered a new trial to determine if 10x's products infringe reconstructed patents held by Bio-Rad Laboratories.

The overall revenue decrease was buoyed by 19 percent year-over-year growth in Life Science segment revenues due to strong PCR-related sales.

According to the registry's first dataset, more than 65 million tests have been manufactured and shipped across the US.

The listing enables assay developers and testing labs in the US to access the instrument for COVID-19 testing, the firm said.

10x asked the US District Court for the Northern District of California to dismiss a suit, while another district court judge denied a 10x motion to dismiss.

Pages

Reuters reports that Germany is seeking to sequence 5 percent of patient samples that test positive for SARS-CoV-2.

23andMe and Medscape say primary care physicians are increasingly more comfortable with discussing direct-to-consumer genetic testing results.

The publisher of the Science family of journals will allow some authors to place peer-reviewed versions of their papers into publicly accessible repositories.

In Science this week: analysis of genome-wide association studies of chronic kidney disease, and more.